Clinical Trials
11 trialsNCT05533775 2026-06-03
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06084936 2026-06-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06624085 2026-06-03
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT06634589 2026-06-03
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
Phase 1/2 Recruiting
NCT07200375 2026-06-03
GlofitReal
Hoffmann-La Roche
Recruiting
NCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT05169515 2026-05-18
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT06090539 2026-04-14
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04970901 2026-03-13
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
ADC Therapeutics S.A.
Phase 1 Recruiting
NCT06393738 2026-02-10
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Arvinas Inc.
Phase 1 Recruiting
NCT06534437 2025-09-29
JASPIS-01
Ryvu Therapeutics SA
Phase 2 Recruiting